Glossopharyngeal Nerve Blockade for Awake Videolaryngoscope Assisted Endotracheal Intubation in the Morbidly Obese

Gagging Clinical Trial

Official title:

Glossopharyngeal Nerve Blockade for Awake Videolaryngoscope Assisted Endotracheal Intubation in the Morbidly Obese.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01791439
• Other study ID #: 11-201-SDR
• Secondary ID: 11-201-SDR
• Status: Recruiting
• Phase: N/A
• First received: February 10, 2013
• Last updated: February 13, 2013
• Start date: January 2013

Study information

• Verified date: February 2013
• Source: Royal Victoria Hospital, Canada
• Contact: Albert Moore, md
• Phone: 5149341934
• Email: moore_albert[@]hotmail.com
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

The investigators wish to determine if application of 2% lidocaine soaked gauze to the peritonsillar pillars will decrease the amount of gagging caused by awake videolaryngocope assisted tracheal intubation in the morbidly obese.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 24
• Est. primary completion date: April 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• morbid obese patients scheduled for bariatric surgery, with a planned awake intubation.

Exclusion Criteria:

• inability to communicate in English or french

• allergies to any study drugs

• any patient with an American society of anesthesiologists score of 4 or more

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)

Related Conditions & MeSH terms

• Gagging

Intervention

Other:
• lidocaine
Application of lidocaine to the glossopharyngeal nerve.
• placebo

Locations

Country	Name	City	State
Canada	Royal Victoria Hospital	Montreal	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Royal Victoria Hospital, Canada

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Gagging	We will assess the amount of gagging during the awake intubation.	2 minutes	No
Secondary	vital signs	we will asses vital signs during intubation.	2 minutes	No
Secondary	lidocaine levels		40 minutes	No